Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 231

1.

Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data.

Salmon JH, Perotin JM, Morel J, Dramé M, Cantagrel A, Ziegler LE, Ravaud P, Sibilia J, Pane I, Mariette X, Gottenberg JE.

Rheumatology (Oxford). 2017 Oct 23. doi: 10.1093/rheumatology/kex403. [Epub ahead of print]

PMID:
29069471
2.

Relationships between ultrasound enthesitis, disease activity and axial radiographic structural changes in patients with early spondyloarthritis: data from DESIR cohort.

Ruyssen-Witrand A, Jamard B, Cantagrel A, Nigon D, Loeuille D, Degboe Y, Constantin A.

RMD Open. 2017 Sep 7;3(2):e000482. doi: 10.1136/rmdopen-2017-000482. eCollection 2017.

3.

Effectiveness of Exercise Programs in Ankylosing Spondylitis: A Meta-Analysis of Randomized Controlled Trials.

Pécourneau V, Degboé Y, Barnetche T, Cantagrel A, Constantin A, Ruyssen-Witrand A.

Arch Phys Med Rehabil. 2017 Aug 30. pii: S0003-9993(17)31019-5. doi: 10.1016/j.apmr.2017.07.015. [Epub ahead of print] Review.

PMID:
28860095
4.

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.

Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group.

Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24.

PMID:
28551073
5.

A rare case of rheumatoid pachyleptomeningitis successfully treated with rituximab.

Degboé Y, Fajadet B, Laurent C, Cantagrel A, Constantin A, Ruyssen-Witrand A.

Rheumatology (Oxford). 2017 Jul 1;56(7):1238-1240. doi: 10.1093/rheumatology/kex059. No abstract available.

PMID:
28340133
6.

No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis.

Baradat C, Degboé Y, Constantin A, Cantagrel A, Ruyssen-Witrand A.

RMD Open. 2017 Feb 22;3(1):e000352. doi: 10.1136/rmdopen-2016-000352. eCollection 2017.

7.

Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study.

Alten R, Nüßlein HG, Mariette X, Galeazzi M, Lorenz HM, Cantagrel A, Chartier M, Poncet C, Rauch C, Le Bars M.

RMD Open. 2017 Feb 13;3(1):e000345. doi: 10.1136/rmdopen-2016-000345. eCollection 2017.

8.

Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry.

Latourte A, Gottenberg JE, Luxembourger C, Pane I, Claudepierre P, Richette P, Lafforgue P, Combe B, Cantagrel A, Sibilia J, Flipo RM, Gaudin P, Vittecoq O, Schaeverbeke T, Dougados M, Sellam J, Ravaud P, Mariette X, Seror R.

Rheumatology (Oxford). 2017 Apr 1;56(4):629-637. doi: 10.1093/rheumatology/kew476.

PMID:
28053274
9.

The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study.

Mariette X, Alten R, Nüßlein HG, Galeazzi M, Lorenz HM, Cantagrel A, Chartier M, Poncet C, Rauch C, Le Bars M.

Joint Bone Spine. 2017 Oct;84(5):571-576. doi: 10.1016/j.jbspin.2016.10.011. Epub 2016 Dec 30.

10.

Infectious risk associated to orthopaedic surgery for rheumatoid arthritis patients treated by anti-TNFalpha.

Mabille C, Degboe Y, Constantin A, Barnetche T, Cantagrel A, Ruyssen-Witrand A.

Joint Bone Spine. 2017 Jul;84(4):441-445. doi: 10.1016/j.jbspin.2016.06.011. Epub 2016 Sep 20.

PMID:
27663754
11.

Association between RANK, RANKL and OPG polymorphisms with ACPA and erosions in rheumatoid arthritis: results from a meta-analysis involving three French cohorts.

Ruyssen-Witrand A, Degboé Y, Cantagrel A, Nigon D, Lukas C, Scaramuzzino S, Allanore Y, Vittecoq O, Schaeverbeke T, Morel J, Sibilia J, Cambon-Thomsen A, Dieudé P, Constantin A.

RMD Open. 2016 Sep 8;2(2):e000226. doi: 10.1136/rmdopen-2015-000226. eCollection 2016.

12.

Performance of patient-reported outcomes in the assessment of rheumatoid arthritis disease activity:the experience of the ESPOIR cohort.

Che H, Combe B, Morel J, Cantagrel A, Gossec L, Lukas C.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4):646-54. Epub 2016 Jun 22.

PMID:
27384748
13.

Impact of urine dipstick abnormalities in patients on biotherapies.

Vandewoestyne S, Zabraniecki L, Jamard B, Cestac P, Cantagrel A, Civade E.

Joint Bone Spine. 2017 Mar;84(2):239-240. doi: 10.1016/j.jbspin.2016.04.003. Epub 2016 May 26. No abstract available.

PMID:
27238196
14.

Effect of age at rheumatoid arthritis onset on clinical, radiographic, and functional outcomes: The ESPOIR cohort.

Krams T, Ruyssen-Witrand A, Nigon D, Degboe Y, Tobon G, Fautrel B, Berenbaum F, Cantagrel A, Constantin A.

Joint Bone Spine. 2016 Oct;83(5):511-5. doi: 10.1016/j.jbspin.2015.09.010. Epub 2016 Mar 15.

PMID:
26992954
15.

Autoantibodies to human citrullinated fibrinogen and their subfamilies to the α36-50Cit and β60-74Cit fibrin peptides similarly predict radiographic damages: a prospective study in the French ESPOIR cohort of very early arthritides.

Cornillet M, Ajana S, Ruyssen-Witrand A, Constantin A, Degboé Y, Cantagrel A, Meyer O, Serre G, Nogueira L.

Rheumatology (Oxford). 2016 Mar 8. pii: kew014. [Epub ahead of print]

PMID:
26961744
16.

Glucocorticoid-sparing in patients suffering from rheumatoid arthritis and treated with tocilizumab: the SPARE-1 study.

Saraux A, Rouanet S, Flipo RM, Poncet JC, Fardellone P, Hilliquin P, Idier I, Cantagrel A.

Clin Exp Rheumatol. 2016 Mar-Apr;34(2):303-10. Epub 2016 Mar 3.

PMID:
26941130
17.

Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry.

Lahaye C, Soubrier M, Mulliez A, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, Le Loët X, Shaeverbeke T, Ravaud P, Mariette X, Gottenberg JE; French Society of Rheumatology.

Rheumatology (Oxford). 2016 May;55(5):874-82. doi: 10.1093/rheumatology/kev437. Epub 2016 Jan 27.

PMID:
26822072
18.

New autoantibodies associated with rheumatoid arthritis recognize posttranslationally modified self-proteins.

Cantagrel A, Degboé Y.

Joint Bone Spine. 2016 Jan;83(1):11-7. doi: 10.1016/j.jbspin.2015.10.003. Epub 2015 Nov 27. Review.

PMID:
26639222
19.

Predictive value of autoantibodies from anti-CCP2, anti-MCV and anti-human citrullinated fibrinogen tests, in early rheumatoid arthritis patients with rapid radiographic progression at 1 year: results from the ESPOIR cohort.

Degboé Y, Constantin A, Nigon D, Tobon G, Cornillet M, Schaeverbeke T, Chiocchia G, Nicaise-Roland P, Nogueira L, Serre G, Cantagrel A, Ruyssen-Witrand A.

RMD Open. 2015 Nov 26;1(1):e000180. doi: 10.1136/rmdopen-2015-000180. eCollection 2015.

20.

A new classification of HLA-DRB1 alleles based on acid-base properties of the amino acids located at positions 13, 70 and 71: impact on ACPA status or structural progression, and meta-analysis on 1235 patients with rheumatoid from two cohorts (ESPOIR and EAC cohort).

Ruyssen-Witrand A, van Steenbergen HW, van Heemst J, Gourraud PA, Nigon D, Lukas C, Miceli-Richard C, Jamard B, Cambon-Thomsen A, Cantagrel A, Dieudé P, van der Helm-van Mil AH, Constantin A.

RMD Open. 2015 Nov 19;1(1):e000099. doi: 10.1136/rmdopen-2015-000099. eCollection 2015.

Supplemental Content

Loading ...
Support Center